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A B S T R A C T
The long-term effects of vagus nerve stimulation (VNS) on seizure frequency were studied in 50 patients
with epilepsy and learning disabilities. Mean observation time was 4.6 years. At follow-up, none of the
patients was seizure-free, 25% had more than 50% seizure reduction, and 46% had some seizure
reduction, but less than 50%. The discontinuation rate was 18%. Our results indicate that, like
antiepileptic drugs, VNS does not have such a good seizure-reducing effect in patients with epilepsy and
learning disabilities compared with the general epilepsy population.
 2010 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Approximately 20% of the adult epilepsy population has
learning disabilities (LD), and the occurrence of epilepsy increases
with the severity of LD.1 The chances of achieving seizure control in
patients with epilepsy and LD is poorer than in those without LD,
with 45% of epilepsy patients with LD being refractory to
antiepileptic drugs (AEDs), as compared with approximately 30%
of the total epilepsy population.2,3
The most difﬁcult-to-control epilepsies are found in this sub-
population. For example, in epileptic encephalopathies, such as
Lennox–Gastaut syndrome andDravet syndrome, the seizures are
mostly pharmacoresistant.4,5 Nevertheless, many of these
patients have a heavy drug burden despite the fact that
individuals with LD appears to be more prone to central nervous
side effects from AEDs than those without LD.6,7 Patients with
epilepsy and LD are a very heterogeneous patient group
necessitating that the treatments are tailored to every individual
patient, with the aim of obtaining an optimal balance between
seizure reduction and side effects.
Vagus nerve stimulation (VNS) is an established treatment
option that is offered to patients with drug-resistant seizures
and who after evaluation are not candidates for epilepsy
surgery. The seizure-reducing effect of VNS may increase
gradually over 18–24 months of treatment.8 In a prospective* Corresponding author at: Epilepsisenteret – SSE, Postboks 53, 1306 Bærum
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doi:10.1016/j.seizure.2010.10.0023-year follow-up study of adult patients more than 50% seizure
reduction was reported in 43% of the patients.9 Additionally,
other studies have described subjective improvements in
various quality-of-life measurements during VNS treatment,
independent of the effect on the seizure frequency.10–12 Side-
effects of VNS treatment are mainly stimulation-related and
tend to decrease over time.
A non-pharmacological treatment like VNS is to be warmly
welcomed in patients with severe epilepsy and LD. However, it is
not evident that persons with LD obtain the same seizure-reducing
effect from VNS treatment as persons without LD. Responder rates
(i.e. those having more than 50% seizure reduction) varying from
28% to 68% have been reported.13,14
The purpose of this open, uncontrolled, retrospective study was
to analyze the efﬁcacy and tolerability of VNS treatment in
Norwegian patients with drug-resistant epilepsy and LD. We also
wanted to explore the efﬁcacy of VNS in different sub-groups of
these patients.
2. Materials and methods
All those patients aged 14 years or older, and with a
combination of LD and epilepsy, who had had a VNS implantation
at The National Hospital in Oslo in the period between October
1997–May 2008 were included in the study. All the patients had
been followed up at The National Centre for Epilepsy, located just
outside Oslo, and their demographic and electroclinical data were
retrospectively obtained from the patients’ medical records at the
centre. Patients’ epilepsies were classiﬁed according to the
recommendations of the International League Against Epilepsy
in 1989.15 Each patient had been diagnosed with learningvier Ltd. All rights reserved.
Table 1
Demographic and clinical features.
Clinical data N=48
Male/female 27/21
Mean age at onset of epilepsy (years) 3.5 (0–14)
Mean duration of epilepsy (years) 29 (10–55)
Number of previously tried AEDs 9 (4–15)
Learning disability, mild 21
Learning disability, moderate 16
Learning disability, severe 8
Learning disability, profound 1
Learning disability, degree not known 2
Mean age at VNS implant (years) 27 (14–53)
Epilepsy aetiology N=48
Unknown/known 25/23
Type of aetiology
CNS infection 5
Cortical dysplasia 3
Traumatic brain injury 2
Birth-related asphyxia 5
Cerebrovascular insult 1
Encephalopathia induced by cytostatic agents 1
TSC 3
Rett syndrome 1
Dravet syndrome 1
Klinefelter syndrome 1
Epilepsy syndrome
Focal 24
Focal symptomatic 15
Focal cryptogenic 9
Generalized 24
Generalized symptomatic 10 (LGS: 7)
Generalized cryptogenic 14 (LGS: 6)
AED: Antiepileptic Drugs; VNS: Vagus Nerve Stimulation; TSC: Tuberous Sclerosis
Complex.
Table 2
Effects of VNS treatment.
>50%
seizure
reduction
<50%
seizure
reduction
No
seizure
reduction
TSC (n=3) 1 2
Dravet syndrome (n=1) 1
Rett syndrome (n=1) 1
LGS (n=13) 5 5 3
LGS<18 years (n=4) 2 1 1
LGS>18 years (n=9) 3 4 2
Focal symptomatic epilepsy (n=15) 4 6 5
Focal cryptogenic epilepsy (n=9) 1 6 2
Focal epilepsy (all) (n=24) 5 12 7
Generalized symptomatic
epilepsy (n=10)
3 4 3
Generalized cryptogenic
epilepsy (n=14)
4 7 3
Generalized epilepsy (all) (n=24) 7 11 6
Symptomatic epilepsy (all) (25) 7 10 8
Cryptogenic epilepsy (all) (23) 5 13 5
TSC: Tuberous Sclerosis Complex; LGS: Lennox–Gastaut Syndrome.
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severe (IQ 20–34), or profound (IQ < 20).16
The patients and their caregivers were contacted and asked
to complete a questionnaire. Two patients had died during the
follow-up period, and their relatives were not contacted
regarding the questionnaire. Based on the medical records,
the patients’ seizure diaries, and the information given by the
caregivers, the patients’ seizure types, frequencies, and dura-
tions, their postictal condition, and their overall well-being were
assessed both over a 6-month baseline period prior to VNS
implantation, and also in the follow-up period after the
implantation.
3. VNS stimulation parameters
The VNS was started 1–2 days after the operation with quick
ramp-up procedure. The standard initial parameters were:
output current (OC) 0.25 mA, frequency 20 Hz, pulse width
250 ms, on-time 30 s, and off-time 5 min. The OC was increased
by 0.25 mA every other day up to 1 mA, if the stimulation was
well-tolerated. Follow-up visits were usually every threemonths.
The parameters were adjusted individually according to the
effect and tolerance, and changes in on–off parameters were
attempted in those who experienced no reduction in seizure
frequency.
4. Results
50 patients fulﬁlled the inclusion criteria. Due to local infection,
in two patients the devices were explanted after 5 and 8 months,
respectively. Excluding these two patients, the mean follow-up
period was 4.6 years (range: 1.3–11.9 years). For ﬁve patients, the
devices were explanted due to lack of efﬁcacy. One patient died
during the follow-up period from a disease unrelated to the
epilepsy. Another patient died in sudden unexpected death in
epilepsy (SUDEP). Thus, the discontinuation rate of the patient
group was 18%.
The generator was replaced in eight patients due to end of
battery life, and three of these patients have now received their
third generator.
Out of 48 caregivers, 34 (71%) completed and returned the
questionnaire.
Table 1 summarizes the demographic and clinical features of
the patients.
4.1. Surgical complications
Two patients developed local infections necessitating device
removal. In one patient with tuberous sclerosis complex (TSC) the
operation was unusually prolonged, and the patient woke from
anaesthesia with a unilateral central facial palsy. This could have
been due to a thromboembolic episode, although a CT scan did not
reveal a cerebral infarction. The facial palsy ameliorated after
about 6 months.
4.2. AED treatment
Out of 48 patients, 29 (63%) changed their drug treatment (type
of AED and/or dosage) during the follow-up period. Before
implantation the patients were taking an average of 2.4 AEDs,
and this number was unchanged at follow-up.
4.3. Effect on seizure frequency
At follow-up, none of the patients was seizure-free. Twelve
patients (25%) hadmore than 50% reduction in seizure frequency,i.e. they were therapy responders, while 22 patients (46%) had a
reduction in seizure frequency, but less than 50% compared with
baseline frequency. In 14 patients (29%) the seizure frequency
did not change. Table 2 shows the effects of VNS treatment on
seizure frequency in different sub-groups of the patients.
Unfortunately, these subgroups are too small to allow evaluation
of which disorders beneﬁted most from VNS treatment. However,
there was a tendency for a better effect in patients with Lennox–
Gastaut syndrome than in the rest of the population (38%
responders in the Lennox–Gastaut syndrome group compared
with 25% in the whole population). Likewise, it was not possible
to draw ﬁrm conclusions about predictive factors regarding age
at implantation, mental age, epilepsy syndrome, or epilepsy
aetiology.
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(mean OC: 1.9 mA) compared with non-responders (mean OC:
1.65 mA). Four patients became responders on normal cycling
(30 s on-time, and 5 or 3 min off-time). Five patients who did not
respond on normal cycling, became responders on rapid cycling
(7 s on-time, and 12 or 18 s off-time), and three other patients
became responders on intermediate cycling (21 or 14 s on-time,
and 0.8–1.8 min off-time).
In 13 patients, the pulse width was increased from 250 to
500 ms in an attempt to achieve better seizure control. However,
only one of these patients achieved some reduction in seizure
frequency, but less than 50%. Six patients reported some seizure
deterioration, and three patients reported adverse events on
500 ms. These side-effects stopped when the pulse width was
returned to 250ms.
4.4. Results from the questionnaires
According to answers from the questionnaire (caregivers of 34
patients), 22 patients had less severe seizures after VNS
implantation, as both the seizures and the postictal periods were
of shorter duration. In 12 patients the caregivers reported reduced
use of benzodiazepines to terminate prolonged seizures. 13
patients were reported to have becomemore alert, and 13 patients
were, according to their caregivers, in a better mood following VNS
implantation. 19 patients reported some effect using the magnet
(shorter, milder, or abortive seizures).
At follow-up, 14 patients were reported to have side-effects like
voice change, mild dysphagia, or throat pain.
5. Discussion
In this study, 25% of the patient cohort was considered as VNS
treatment responders, i.e. they had greater than 50% seizure
reduction. However, no patients became seizure-free. The numbers
were too small to reach ﬁrm conclusions about the effect of VNS in
different patient sub-groups, e.g. different ages, different degrees
of LD, and different epilepsy syndromes. But, also many patients
without seizure reduction, reported that they nevertheless had
some form of beneﬁcial effect from the treatment. This included
shorter seizures or postictal periods, less consumption of
benzodiazepines, termination of seizures using the magnet, better
mood, or they were more alert. This result concurs with results
from other studies reporting an improvement in the quality of life
as a consequence of VNS treatment.10–13
Our results are also in agreement with the ﬁndings from a long-
term, prospective study in a similar population to ours. Huf et al.13
performed at prospective study in 40 adult epilepsy patients with
LD living in long-term care facilities, and found that after two years
of VNS treatment, seizure frequencywas reduced by at least 50% in
28% of the patients. However, Andriola and Vitale14 demonstrated
much better results in a retrospective study of 21 patients with LD
(adults and children), withmore than 50% seizure reduction in 68%
of patients after six months follow-up.
There are several studies of the effect of VNS treatment in
patients with Lennox–Gastaut syndrome or Lennox–Gastaut-like
disorders. Five of these studies had a prospective design and
disclosed a greater than 50% seizure reduction in 21–60% of
children,17,18 and in 46–63% in mixed populations with both
children and adults.19,20 However, Parker et al.21,22 followed 16
children with epileptic encephalopathies and found no signiﬁcant
improvement in seizure frequency during the ﬁrst year, some
improvement after two years, and then a subsequent deterioration
during the third year of the study.
Retrospective studies tend to showmore promising results than
prospective studies, with over 50% seizure reduction in 54–90% ofchildren11,23,24 and in 67% in a study of children and adults.25 In
some of these studies it is possible to compare patients with
Lennox–Gastaut syndrome with patients with other forms of
epilepsy, and these comparisons suggest that children with
Lennox–Gastaut syndrome tend to have better results than
patients with other epilepsy syndromes.18,23,26 This might also
be true for older patients,20 and our results strengthen such an
assumption.
Previously, we have performed two studies at our centre on the
efﬁcacy and tolerability of VNS in unselected patients with
difﬁcult-to-control seizures. Nakken et al.27 found that in a group
of 47 adult patients 34% had greater than 50% seizure reduction
after a mean follow-up period of 2.7 years. In this population, eight
(17%) had a learning disability, and patients with Lennox–Gastaut
syndrome experienced only a modest reduction in seizure
frequency. In a study including 46 children, Bremer et al.28 found
a greater than 50% seizure reduction in 43% after a mean follow-up
of 2.6 years. Included were 11 children with Lennox–Gastaut
syndrome, and 45% of them achieved a greater than 50% seizure
reduction.
The current study is subject to certain limitations, and thus, the
results should be interpreted with caution. Firstly, our centre is a
tertiary referral centre, and patients recruited from such centres
are usually the most difﬁcult-to-treat, and therefore our patient
group is subject to selection bias. Secondly, 2/3 of our cohort
altered their AED treatment during the follow-up period; for an
ideal research group AED treatment would have remained
constant throughout the study period. However, as the patients
previously had tried a mean of 10 AEDs, further adjustment of the
dosing or drug regimens should not be expected to make a
signiﬁcant difference. Thirdly, our study is retrospective and
uncontrolled, with all the limitations such a design implies.
Comparing different studies on the effects and tolerability of
VNS is difﬁcult due to variations in the populations studied and the
follow-up time. Additionally, confounding factors are not always
taken into consideration. The VNS-related studies from our centre
indicate that VNS has a better seizure-reducing effect in children
than adults.27,28 Andriola et al.14 described a nine-year old patient,
successfully treatedwith VNS for three years.When the devicewas
explanted because of postoperative infection after battery change,
the seizures did not increase, and therefore the device was
therefore not re-implanted. This demonstrates that the natural
history of epilepsy in some children can be benign and might
perhaps explain why VNS has a better effect in children.
Aldenkamp et al.17 found that the VNS effect was most prominent
in the group with the highest mental age at baseline, which
suggests that learning disability might be a negative prognostic
factor. However, VNS seems to have a seizure-reducing effect in
patients with Lennox–Gastaut syndrome, which is at least similar
to the effect reported in the rest of the epilepsy population,25 and
children with Lennox–Gastaut syndrome might experience a
better effect than adults.
Since our study was retrospective, it was not possible to assess
whether there was a loss of VNS efﬁcacy over time in some of the
patients. Rossignol et al.18 reported that four patients using VNS
therapy who had an initial response at six months, lost seizure
control after 24 months, and Parker et al.22 demonstrated an
increase in VNS efﬁcacy for two years, but a loss of efﬁcacy in the
third year. Loss of efﬁcacy after sixmonths could indicate a placebo
effect, and loss of efﬁcacy after 24 months may suggest
development of tolerance, similar to pharmacological tolerance.
While VNS therapy offers some advantages, it also incurs some
problems when treating patients with LD and epilepsy. One
advantage is that VNS therapy does not result in interactions with
AEDs or other medications. Further, as soon as the device is
implanted, there are no problems with compliance. However, the
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group mean that it is difﬁcult to explain the concept of VNS and
prepare the patients for the treatment procedures. Similarly, after
implantation it is often difﬁcult to evaluate the patients’ tolerance
to the different stimulation parameters. VNS therapy lacks
measurable response parameters, equivalent to the serum con-
centrations of AEDs, with which to monitor and adjust the
stimulation individually. However, although it might be assumed
that postoperative infections could be a problem in a patient group
that does not always treat their bandages with care, this problem
was no more frequent in this study, with an infection rate of 4.3%,
compared to 3–6% reported in other studies.29,30
One patient died in SUDEP after nine years of successful VNS
treatment. About four months prior to death, she had fallen on ice,
and had subsequently experienced a worsening of her seizure
control. 3.5 months later, the VNS was explanted and a new one
implanted. 11 days after the operation she was found dead.
Investigations post mortem did not reveal any problems with the
new stimulator, but the cable was twisted. In some studies SUDEP
has been associated with changes in AED treatment,31,32 and it is
possible there could be a parallel in VNS treatment, with increased
risks of SUDEP related to abrupt changes in stimulation.
The utility of the magnet to abort seizures is limited in these
patients, as many of them are unable to recognize and express the
appearance of simple partial seizures/auras. However, relatives and
carers are able touse themagnetduringongoing seizures, and in this
study 56% reported some beneﬁcial effect from using the magnet.
6. Conclusions
The results of this study indicate thatVNSdoesnothave the same
favourable seizure-reducingeffect inepilepsypatientswith learning
disabilities as thegeneral epilepsypopulation. Inour study, only25%
of the patients had >50% reduction in seizure frequency. The most
challenging question to be addressed in future studies is which sub-
groups are likely to beneﬁt the most from VNS treatment.
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